Aztreonam Lysine for Inhalation (AZLI)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Complication of Transplanted Lung
Conditions
Complication of Transplanted Lung
Trial Timeline
Mar 1, 2013 → Apr 1, 2015
NCT ID
NCT01469364About Aztreonam Lysine for Inhalation (AZLI)
Aztreonam Lysine for Inhalation (AZLI) is a approved stage product being developed by Gilead Sciences for Complication of Transplanted Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT01469364. Target conditions include Complication of Transplanted Lung.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01469364 | Approved | Completed |
Competing Products
20 competing products in Complication of Transplanted Lung